Connect with the Tandem Mobi system
Dexcom G7 powers the Tandem Mobi system,
communicating via Bluetooth® to create an
easy-to-use system that automates insulin dosing. Experience innovative features like mobile bolus, Personal Profiles, and multiple infusion sets.
Trusted partners in diabetes management
Dexcom and Tandem have created life-changing diabetes management solutions with over a decade of collaboration.
Dexcom G7
- The most accurate CGM system1,2
- The only CGM that offers no fingersticks* from day 1
- 60% smaller§
- The fastest CGM—only 30-minute warmup||
- The only CGM system with app features that help protect from severe hypoglycemia and DKA.
*Fingersticks required for diabetes treatment decision if symptoms or expectations do not match readings.
Tandem Mobi
- The world's smallest durable AID system7
- Unrivaled wearability—wear it (on body), clip it (on clothes), slip it (in pocket)
- Pump button for checking the pump status lights and bolus
- Control-IQ Technology uses Dexcom G7 glucose values to predict and help protect from highs and lows.
- Create up to 6 Personal Profiles based on insulin need
Meet Dexcom CGM
Meet Dexcom CGM, you have the freedom to choose the insulin pump that works best for you. Glucose readings are sent to your smartphone‡ or Dexcom receiver—without fingersticks.*
*Fingersticks required for diabetes treatment decision if symptoms or expectations do not match readings.
Do you have questions about the Tandem Mobi system?
†Bolus delivery from the t:connect mobile app requires a compatible smartphone model and operating system, an app update, a remote software update on the customer’s t:slim X2 insulin pump and additional training. Only available to Tandem Diabetes Care customers who reside in the United States. ‡Smart device sold separately. For a list of compatible devices, visit dexcom.com/compatibility. §Compared to prior generation Dexcom CGM system. ||Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
1 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. https://www.accessdata.fda.gov/cdrh_docs/reviews/K213919.pdf.
2 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf.
3 Brown SA, et al. N Engl J Med. 2019.381(18).1707-17. 6 Criego AB, Carlson AL, Brown SA, et al. Diabetes Technol Ther. 2024;26(1):11-23. doi:10.1089/dia.2023.0364. 7 As of Feb. 2024. Data on file, Tandem Diabetes Care.
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.